RINVOQ 15 mg prolonged-release tablets
Sponsors
Hospital Universitario La Paz, Universitaetsklinikum Erlangen AöR, Universitaetsklinikum Erlangen AöR, Universitaetsklinikum Erlangen AöR, Sint Maartenskliniek Stichting, Care Arthritis Ltd.
Conditions
Acute Anterior UveitisAtopic dermatitisAxial SpondyloarthritisLong CovidPsoriatic arthritisRheumatoid arthritispsoriatic arthritis and axial spondyloarthritis
Phase 3
A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
RecruitingCTIS2023-508251-39-00
Start: 2020-09-18Target: 370Updated: 2026-01-20
Long Covid (LC)-Revitalize - A Long Covid Repurposed Drug Study
WithdrawnCTIS2025-522611-42-00
Target: 75Updated: 2026-02-25
Phase 4
Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment response (DermAtOmics-II)
RecruitingCTIS2023-506165-62-00
Start: 2023-09-25Updated: 2025-08-20
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing
CompletedCTIS2024-512669-15-00
Start: 2022-03-24End: 2025-01-22Target: 20Updated: 2024-03-20
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases
RecruitingCTIS2025-520757-36-00
Start: 2025-09-15Target: 200Updated: 2026-01-13
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
(UP-FOR-U)
Not yet recruitingCTIS2025-522118-21-00
Target: 30Updated: 2026-03-13